Pertuzumab adds 16 months survival benefit to trastuzumab plus chemotherapy for HER2-positive metastatic breast cancer

Bookmark and Share
Published: 28 Sep 2014
Views: 4179
Dr Sandra Swain - Washington Cancer Institute, Washington, USA

Dr Swain talks to ecancertv at ESMO 2014 about the results of the CLEOPATRA trial, which demonstrated significant survival benefits for patients with HER2 breast cancer when treated with a combination of pertuzumab, trastuzumab and chemotherapy.

Read the news story or watch the press conference for more.

ecancer's filming at ESMO has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.